Some of you may have been following the news about venture capitalist Martin Shkreli who decided
to raise the price of toxoplasmosis drug Daraprim from $13.50 a pill to $750.
Then one of the scitweeps remembered something interesting:
.@MHendr1cks He's the dude that funded Perlstein's lab!
— Darren Boehning (@boehninglab) September 22, 2015
Of the $2 million seed money, New York-based Retrophin and the Wilsey family foundation in San Francisco have combined to contribute about one-third. The rest has come from angel funders in increments of $10,000 to $400,000, Perlstein says.
Perlstein first caught Retrophin CEO Martin Shkreli’s attention on Twitter, and their exchange led to a meeting at the J.P. Morgan conference in San Francisco.
@MartinShkreli cool, thanks! As I plow ahead with Perlstein Lab, I'll be watching Retrophin with great interest (and Ultragenyx, too)
— Ethan O. Perlstein (@eperlste) January 2, 2014
@eperlste shoot me an email very curious what you're up to
— Martin Shkreli (@MartinShkreli) January 2, 2014
Sounds like the start of a beautiful relationship.